Design and Characterization of PROTAC Degraders Specific to Protein N-terminal Methyltransferase 1
Overview
Affiliations
Protein N-terminal methylation catalyzed by N-terminal methyltransferase 1 (NTMT1) is an emerging methylation present in eukaryotes, playing important regulatory roles in various biological and cellular processes. Although dysregulation of NTMT1 has been linked to many diseases such as colorectal cancer, their molecular and cellular mechanisms remain elusive due to inaccessibility to an effective cellular probe. Here we report the design, synthesis, and characterization of the first-in-class NTMT1 degraders based on proteolysis-targeting chimera (PROTAC) strategy. Through a brief structure-activity relationship (SAR) study of linker length, a cell permeable degrader 1 involving a von Hippel-Lindau (VHL) E3 ligase ligand was developed and demonstrated to reduce NTMT1 protein levels effectively and selectively in time- and dose-dependent manners in colorectal carcinoma cell lines HCT116 and HT29. Degrader 1 displayed DC = 7.53 μM and D > 90% in HCT116 (cellular IC > 100 μM for its parent inhibitor DC541). While degrader 1 had marginal cytotoxicity, it displayed anti-proliferative activity in 2D and 3D culture environment, resulting from cell cycle arrested at G0/G1 phase in HCT116. Label-free global proteomic analysis revealed that degrader 1 induced overexpression of calreticulin (CALR), an immunogenic cell death (ICD) signal protein that is known to elicit antitumor immune response and clinically linked to a high survival rate of patients with colorectal cancer upon its upregulation. Collectively, degrader 1 offers the first selective cellular probe for NTMT1 exploration and a new drug discovery modality for NTMT1-related oncology and diseases.
Characteristic roadmap of linker governs the rational design of PROTACs.
Dong Y, Ma T, Xu T, Feng Z, Li Y, Song L Acta Pharm Sin B. 2024; 14(10):4266-4295.
PMID: 39525578 PMC: 11544172. DOI: 10.1016/j.apsb.2024.04.007.
Application of PROTACs in Target Identification and Target Validation.
Liu Y, Liang J, Zhu R, Yang Y, Wang Y, Wei W Acta Mater Med. 2024; 3(1):72-87.
PMID: 39373008 PMC: 11452161. DOI: 10.15212/amm-2024-0010.
Cui M, Wu W, Li Q, Qi G, Liu X, Bai J Cells. 2024; 13(2).
PMID: 38247835 PMC: 10814310. DOI: 10.3390/cells13020143.
The involvement of E3 ubiquitin ligases in the development and progression of colorectal cancer.
Chen J, Feng H, Wang Y, Bai X, Sheng S, Li H Cell Death Discov. 2023; 9(1):458.
PMID: 38104139 PMC: 10725464. DOI: 10.1038/s41420-023-01760-z.
Tan L, Li W, Su Q PeerJ. 2023; 11:e16263.
PMID: 37901469 PMC: 10607204. DOI: 10.7717/peerj.16263.